Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis David González de Olano, MD, Iván Álvarez-Twose, MD, María I. Esteban-López, MD, Laura Sánchez-Muñoz, MD, PhD, María D. Alonso Díaz de Durana, MD, Arantza Vega, MD, PhD, Andres García-Montero, MD, PhD, Eloina González-Mancebo, MD, PhD, Teresa Belver, MD, María D. Herrero-Gil, MD, Montserrat Fernández-Rivas, MD, PhD, Alberto Orfao, MD, PhD, Belén de la Hoz, MD, PhD, Mariana C. Castells, MD, PhD, Luis Escribano, MD, PhD Journal of Allergy and Clinical Immunology Volume 121, Issue 2, Pages 519-526 (February 2008) DOI: 10.1016/j.jaci.2007.11.010 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Evolution of specific-IgE values throughout the years undergoing VIT. Differences between baseline determination and following years: # versus ∗P < .041; # versus ∗∗P < .002; # versus ∗∗∗P < .005; # versus ∗∗∗∗P < .003. Journal of Allergy and Clinical Immunology 2008 121, 519-526DOI: (10.1016/j.jaci.2007.11.010) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions